The group is persevering with Granite, but funds might be hard to come by.

First-in-human trial initiations reveal four KRAS assets.

For $850m up front Roche gets to challenge Pfizer.

A US adcom strongly recommends restricting Keytruda, Opdivo and Tevimbra use to PD-L1 expressers.

But the reasons for its all-stock acquisition of AcroImmune seem more prosaic.

But some phase 3 details are unconfirmed, and phase 2 data haven’t shed light on the biggest question.